The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis.
Not Applicable
- Conditions
- Pulmonary tuberculosis
- Registration Number
- JPRN-UMIN000043849
- Lead Sponsor
- Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital
- Brief Summary
The data from 252 patients in the development cohort and 165 patients in the validation cohort were analyzed, of whom 39 (15.5%) and 17 (10.3%), respectively, died in the hospital. The disease severity score (named the AHL score) included three clinical parameters: activities of daily living (semi-dependent, 1 point; totally dependent, 2 points); hypoxemia (1 point), and lymphocytes (< 720/mL, 1 point).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 165
Inclusion Criteria
Not provided
Exclusion Criteria
Disseminated tuberculosis (ie, positive M. tuberculosis PCR or culture test results for urine, blood, or cerebrospinal fluid) or a history of tuberculosis treatment in the 10 years before recruitment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In-hospital mortality
- Secondary Outcome Measures
Name Time Method ength of hospital stay Duration of sputum culture conversion of acid fast bacilli